Factors linked to severe dermatomyositis in Caribbean adults
Official title: Severity Factors of Dermatomyositis in the Caribbean Population - DM-ANTILLES
Run by Centre Hospitalier Universitaire de la Guadeloupe · NCT07265999 · Data updated 2026-11-12
See if specific clinical, demographic, and ancestral factors are linked to more severe dermatomyositis in adults of Caribbean ancestry living in Guadeloupe.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 16 Years and up |
| Sex | All |
| Enrollment | 10 (estimated) |
| Sponsor | Centre Hospitalier Universitaire de la Guadeloupe Academic / other |
| Locations | 1 site (Pointe-à-Pitre) |
| Status | Recruiting |
| Started | July 16, 2021 |
| Main results expected | July 16, 2029 |
| Study ends | July 16, 2029 |
| Registry record updated | December 5, 2025 |
| Trial ID | NCT07265999 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (16 years or older) living in Guadeloupe with dermatomyositis diagnosed per the 2003 ENMC criteria who have parents or grandparents from the Caribbean, are affiliated with a social security scheme, and can provide informed consent are ideal candidates.
✕Probably not a fit
Patients who began intravenous immunoglobulins, corticosteroids, or immunosuppressants within the month before diagnosis, those under legal protection or deprived of liberty, or those not resident in Guadeloupe or without Caribbean ancestry are unlikely to be eligible or to directly benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational project will identify new cases of dermatomyositis in Guadeloupe and characterize the disease in an overseas Caribbean population. Adults meeting the 2003 ENMC diagnostic criteria who have parents or grandparents from the Caribbean and who reside in Guadeloupe will be enrolled after giving informed consent. Investigators will collect clinical, laboratory, imaging, cancer-screening, and diagnostic-timeline data to document visceral involvement and severity at diagnosis. Statistical analysis will look for demographic, ancestral, diagnostic delay, and clinical factors associated with more severe presentations to inform earlier, tailored management.
Why it matters
Potential benefit: If successful, the findings could help clinicians identify higher-risk patients earlier and tailor care to reduce complications and improve outcomes.
How similar studies have gone: This approach is largely novel for Caribbean dermatomyositis, although similar observational work has identified unusually severe phenotypes in other autoimmune diseases in overseas populations.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient with a diagnosis of dermatomyositis according to the 2003 ENMC criteria * Patient with parents or grandparents originating from the Caribbean arc * Patient aged 16 years or older * Patient residing in Guadeloupe * Patient (or legal representative) who has received information about the study and has signed the informed consent form * Patient affiliated with a social security scheme Exclusion Criteria: * Patient who started treatment with intravenous immunoglobulins, corticosteroids, or immunosuppressants within the month prior to the diagnosis of dermatomyositis * Patient under legal protection (guardianship or trusteeship) or deprived of liberty
Where it's running
-
CHU de la Guadeloupe
Pointe-à-Pitre, Guadeloupe Recruiting
Study contacts
- Principal investigator: nadège cordel, MD PhD — CHU de la Guadeloupe
- Study coordinator: melanie petapermal, Master degree
- Email: melanie.petapermal@chu-guadeloupe.fr
- Phone: +590590934667
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Anti-CD19/BCMA universal CAR-T cell therapy for refractory autoimmune diseases
This will try anti-CD19/BCMA universal CAR-T cell therapy in adults with refractory rheumatoid arthritis, dermatomyositis, systemic lupus, or systemic sclerosis to see if it is safe and can control their disease.
-
Emapalumab for MDA5-positive RP-ILD in adults
This study tests whether emapalumab can help adults with anti-MDA5 positive rapidly progressive interstitial lung disease who have dermatomyositis-related conditions.
-
Long-term follow-up after KYV-101 (CAR T) treatment
This follow-up will test how long KYV-101 CAR T cells persist and record any delayed side effects in people who previously received KYV-101 for autoimmune diseases like lupus nephritis, myasthenia gravis, stiff person syndrome, rheumatoid arthritis, or multiple sclerosis.
-
Tocilizumab treatment for anti-MDA5 positive dermatomyositis in adults
This study will try giving tocilizumab or a placebo to adults with anti-MDA5 positive dermatomyositis to see if it improves symptoms and breathing.
-
Patient-rooted insights to shape myositis science
This global project asks people living with myositis (and their care partners) to share experiences and rank research questions so the community can see which issues matter most.
-
Panniculitis linked to dermatomyositis
This research will see if people with dermatomyositis who develop panniculitis have distinct clinical or tissue (histologic) features compared with panniculitis from other causes.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.